Becoming a Global Specialty Pharmaceutical Company
Established in 2008, Orient PHARMA (OP) is an important subsidiary of the Orient EuroPharma Group. The Company focuses on the innovative R&D and manufacturing of pharmaceuticals, and is dedicated to developing central nervous drugs. In 2017, the Company has more than 180 employees, of which 45% are R&D staff, among which more than 70% have master's and doctoral degrees.
The mission and vision of Orient Pharma is to become a Global Specialty Pharma. In the future, the Company will continue to exert its R&D power, and together with the parent company Orient EuroPharma's strong marketing teams in Taiwan and Southeast Asia, establish a foothold in Asia and expand into the international market in Europe, the Americas and China.
Unanimous Domestic and International Recognition for R&D Quality
Together with multinational and multi-center clinical trial teams, OP’s R&D has the capability to target market-oriented niche products. To date, the Company has two unique and innovative drug development technology platforms, evidencing its R&D capabilities. Located in the Huwei Science Park in Yunlin County, the Company's plant is the first pharmaceutical factory in Taiwan to be built according to PIC/S GMP, EU GMP and US FDA 21 CFR international standards. The quality and stability of all its manufactured pharmaceuticals (tablets and capsules) are ensured, and consistent with the requirements of international partners and customers.Currently, OP has achieved five US FDA drug certifications, namely for muscle relaxant Carisoprodol, diabetes drug Miglito, lipid-lowering drug Pitavastatin, lower blood sugar drug Glyburide and oral anti-infection drug Vancomycin. The lipid-lowering drug, developed by OP, is currently on the Taiwan market, and is also certified by Vietnam and Philippines. Methydur, a new drug for attention deficit hyperactivity disorder has also been licensed in 2018 for the Taiwan market, and awarded the Innovation of the Year of 2019 Taiwan Bio-Industry Organization Awards. OP will be further expanded into Southeast Asia.
2F, No. 368, Sec. 1, Fu Hsing S. Road, Taipei 106, Taiwan, R.O.C.
Pioneering New Ideas and Opportunities
OEP Pharma, located in San Diego, was established in 2019. It has R&D and market development teams to assist North American companies in advancing pharmaceutical innovation and reaching new markets. OEP Pharma has four main lines of business including co-development of 505(b)(2)s, marketing of ANDAs, providing CMO and CDMO services, and licensing and distribution of branded pharmaceuticals in Asia.
5820 Oberlin Dr, Ste101 San Diego, CA 92121